The Effects of Dexmedetomidine Or Remifentanyl Continuous Infusion on End-Tidal Sevoflurane Concentration In patients undergoing Laparoscopic Cholecestectomies, Monitored by Bispectral Analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201611001829308

Enrollment

120

Registered

2016-10-18

Start date

2016-10-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery laparoscopic cholecystectomies

Interventions

placebo (P group).

dexmedetomidine (D group)

remifentanil (R group)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ASA I-II patients scheduled for elective Videolaparoscopic cholecystectomy were included

Exclusion criteria

Exclusion criteria: ). Patients were excluded if they had severe cardiac disease, chronic obstructive lung disease, renal and hepatic insufficiency, endocrine, metabolic or central nervous system disorders, a-2-agonist or antagonist therapy taken, and active upper respiratory infection, those receiving medications known to affect MAC, or having a history of alcohol or drug abuse; and women who were lactating or pregnant.

Design outcomes

Primary

Measure	Time frame
End-tidal CO2 (ETCO2) concentration and end-expiratory concentration of sevoflurane	—

Secondary

Measure	Time frame
hemodynamic parameters and BIS during laparoscopic cholecystectomies	—

Countries

Egypt

Contacts

Public ContactAtteia Gad Anwar

lecturer of anesthesiology and ICU

atteiagad@gmail.com0201273693928

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026